Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Related Articles

Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Pharmacoeconomics. 2016 Mar;34(3):259-72

Authors: Schmier JK, Hulme-Lowe CK

Abstract
Age-related macular degeneration (AMD) is a common ophthalmic condition that can have few symptoms in its early stage but can progress to major visual impairment. While there are no treatments for early-stage AMD, there are multiple modalities of treatment for advanced disease. Given the increasing prevalence of the disease, there are dozens of analyses of cost effectiveness of AMD treatments, but methods and approaches vary broadly. The goal of this review was to identify, characterize, and critique published models in AMD and provide guidance for their interpretation. After a literature review was performed to identify studies, and exclusion criteria applied to limit the review to studies comparing treatments for AMD, we compared methods across the 36 studies meeting the review criteria. To some extent, variation was related to targeting different audiences or acknowledging the most appropriate population for a given treatment. However, the review identified potential areas of uncertainty and difficulty in interpretation, particularly regarding duration of observation periods and the importance of visual acuity as an endpoint or a proxy for patient-reported utilities. We urge thoughtful consideration of these study characteristics when comparing results.

PMID: 26563248 [PubMed - indexed for MEDLINE]

http://ift.tt/2ndTkye